Dallas, TX -- (SBWIRE) -- 03/11/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Bill Barrett Corporation (NYSE:BBG) shares increased 2.87% and closed at $19.73. Canaccord Genuity reiterated its Hold rating and $20.00 price target on Bill Barrett Corporation on Mar. 6.
Additionally, the company, on Feb. 21, reported fourth-quarter net income of $14.0 million or $0.30 per share, compared to a loss of $37.8 million or $0.81 per share last year. Adjusted earnings for the quarter were $0.20 per share. Total operating and other revenues for the quarter dropped to $179.8 million from $208.5 million last year. Analysts expected earnings of $0.10 per share on revenue of $188.3 million for the quarter.
Get Latest News, Updates on BBG Here
Melco Crown Entertainment Ltd (ADR) (NASDAQ:MPEL) shares gained 2.87% to $20.82. The company, on Feb. 27, announced that its two luxurious hospitality establishments, Altira Macau and City of Dreams' Crown Towers bestowed the Forbes Five-Star Hotel Awards by the 2013 Forbes Travel Guide. Altira Macau is proud to have earned the highest rating in both the Hotel and Spa categories for four consecutive years, while City of Dreams' Crown Towers is the first hotel brand in the Cotai region to receive this coveted award.
Is MPEL a Strong Buying Opportunity After The Recent Slump? Find out Here
Grupo Financero Sntdr Mxco SAB de CV ADR (NYSE:BSMX) shares jumped 2.86% and closed at $16.16. The company is a Mexico-based financial institution. The Company is primarily engaged, through its subsidiaries, in the provision of multiple banking services, securities brokerage, financial advice services, as well as other related investment activities.
Is BSMX Signaling a Buy After The Sudden Gain? Don’t Miss Out Free Trend Analysis Here
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares climbed 2.86% and closed at $5.04. The company, on Mar. 6, announced the start of a multicenter, single arm Phase 2 investigator-sponsored study of palifosfamide (ZIO-201) in patients with recurrent metastatic germ cell (testicular and ovarian) tumors who have relapsed on initial platinum-based therapy and high dose chemotherapy, or patients who are not eligible for high dose chemotherapy.
Get latest News, Updates on ZIOP Here
Marketbuzzreport.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Marketbuzzreport.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.marketbuzzreport.com
The assembled information disseminated by Marketbuzzreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Marketbuzzreport.com does expect that investors will buy and sell securities based on information assembled and presented in Marketbuzzreport.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)